Oncopeptides AB (publ) (0RN4.IL)
IOB - IOB Delayed price. Currency in SEK
Add to watchlist
As of 12:47PM BST. Market open.
| Previous close | 3.3525 |
| Open | 3.0700 |
| Bid | 2.9150 x N/A |
| Ask | 3.2200 x N/A |
| Day's range | 3.0350 - 3.1541 |
| 52-week range | 2.8900 - 10.5400 |
| Volume | |
| Avg. volume | 15,135 |
| Market cap | 312.799M |
| Beta (5Y monthly) | -0.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
DUBAI, United Arab Emirates and STOCKHOLM, Sweden, March 27, 2024 (GLOBE NEWSWIRE) -- Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this e
© 2024 Yahoo. All rights reserved.